Introduction {#S0001}
============

Phosphoinositide 3-kinases (PI3Ks) phosphorylate phosphatidylinositol lipids in intracellular membranes at the 3ʹ position of the inositol ring. Class I PI3Ks act at the plasma membrane by phosphorylating phosphatidylinositol-4,5-bisphosphate (PIP2) to produce phosphatidylinositol-3,4,5-triphosphate (PIP3). In addition to catalytic functions, class I PI3Ks also act as scaffold proteins to create regulatory complexes independent of the kinase action of PI3Ks \[[1](#CIT0001)--[3](#CIT0003)\]. Class I PI3Ks have four isoforms (PI3Kα, PI3Kα, PI3Kγ, and PI3Kδ) consisting of a p110 catalytic and regulatory subunit. Based on the regulatory subunit preference, class I PI3Ks are grouped into class IA enzymes (p110β, p110β, and p110δ), which bind to a p85 family regulatory subunit, and the class IB PI3K (p110γ), which binds to p84 or p101 regulatory subunit. PIP3 produced by these PI3Ks binds with effectors that have a PI3K-lipid-binding pleckstrin homology (PH) domain. These effector proteins, including the AKT Ser/Thr protein kinase, regulate various biological processes such as nutrient sensing, survival, cell cycle, migration, and others \[[3](#CIT0003)--[8](#CIT0008)\]. Different isoforms are activated by distinct mechanisms: PI3Kα and PI3Kδ are activated by receptor tyrosine kinase (RTK) and Ras small GTPases, PI3Kγ is activated by Gαγ subunits released following G protein-coupled receptor (GPCR) activation and by Ras, and PI3Kα can be activated by RTKs, Gαγ and the Cdc42 and Rac small GTPases. The catalytic subunits, p110β, p110β, p110γ, and p110δ, are encoded by the *PIK3CA, PIK3CB, PIK3CG*, and *PIK3CD* genes, respectively. Upregulation of class IA PI3K signaling is frequently found in cancer and occurs through various mechanisms, including inactivation of the PI3K antagonizer phosphatase and tensin homolog (PTEN), overactivation of RTKs upstream of PI3K and gain-of-function somatic mutations in genes coding for catalytic subunits \[[9](#CIT0009)--[11](#CIT0011)\]. Among PI3K gene mutations, mutations in *PIK3CA* are the most frequent, with much lower frequency in *PIK3CB* and *PIK3CD* \[[12](#CIT0012)\]. The crucial role of the PI3K pathway in cancer development and progression made this pathway a promising target for cancer treatment \[[13](#CIT0013)--[15](#CIT0015)\]. However, the development of PI3K-targeted drugs has raised a need to investigate the role of PI3K isoforms in wider physiology and pathophysiology. Recent preclinical studies have revealed that PI3Ks plays a critical role in hypertrophy, electrical remodeling, cardiovascular diseases, including cytoskeletal regulation during heart failure, cardioprotection from ischemic injury, and channel activity regulation \[[6](#CIT0006)--[8](#CIT0008),[16](#CIT0016),[17](#CIT0017)\]. In this review, we will focus on the novel role of PI3Kα as a modulator of cytoskeletal integrity, channel activity, Ca^2+^ cycling, and the mechanisms underlying arrhythmogenicity upon PI3Kα inhibition.

PI3K inhibitors in cancer therapy {#S0002}
=================================

The involvement of various PI3K isoforms in cancer made them a prime target for cancer therapies \[[13](#CIT0013)--[15](#CIT0015)\]. The PI3Kα isoform is the main target for solid tumors, and PI3Kδ is targeted in hematological tumors, whereas PI3Kα and PI3Kγ receiving less attention ([Table 1](#T0001)). Since PI3Kα is the functionally-dominant isoform expressed in the heart, in this review, we will focus on the cardiac effects of PI3Kα inhibition.10.1080/19336950.2019.1697127-T0001Table 1.PI3K isoform-specific and pan-PI3K inhibitors.AgentTargetPhaseCancer type/ConditionMajor ToxicitiesCardiac specificNotesRefAlpelisibPI3KαIAdvanced breast cancerHyperglycemia, dermatologic adverse effects, gastrointestinal discomforts, fatigueQTc prolongation \[[18](#CIT0018)--[20](#CIT0020)\]IAdvanced solid tumors  \[[21](#CIT0021),[22](#CIT0022)\]IAdvanced colorectal cancerQTc prolongation \[[23](#CIT0023)\]IAdvanced ovarian, fallopian tube, primary peritoneal, or breast cancer  \[[24](#CIT0024)\]IIEarly Breast cancer No additional benefits with letrozole\[[25](#CIT0025)\]serabelisibIAdvanced solid tumorsAs above, with in addition elevated AST/ALT  \[[26](#CIT0026)\]TaselisibIAdvanced solid tumorsGastrointestinal discomforts, fatigue, hyperglycemia, dermatologic adverse effects, stomatitis, colitis Target mutant PI3Kα isoform \> wild-type PI3Kα, δ, γ \> PI3Kβ\[[27](#CIT0027)\]IAdvanced solid tumors, HR-positive advanced breast cancer  \[[28](#CIT0028)\]IIAdvanced HER2-negative, HR-positive breast cancer  \[[29](#CIT0029)\]Now approvedEstrogen receptor-positive, *PIK3CA*-mutant, locally advanced or metastatic breast cancer  \[[30](#CIT0030)\]GSK2636771PI3KβIAdvanced solid tumorsGastrointestinal discomforts, fatigue, hypophosphatemia, hypocalcemia  \[[73](#CIT0073)\]IPI-549PI3KγIAdvanced solid tumorsGastrointestinal discomforts, dermatologic adverse effects, pyrexia, elevated AST/ALT  \[[74](#CIT0074)\]UmbralisibPI3KδIRelapsed or refractory chronic lymphocytic leukemia or lymphomaGastrointestinal discomforts, fatigue, dermatologic adverse effects, hypokalemia, hematological toxicities (neutropenia, anemia, thrombocytopenia), elevated AST/ALT, pneumonia, colitis Inhibits casein kinase 1ϵ as well\[[75](#CIT0075)\]  IRelapsed or refractory chronic lymphocytic leukemia or mantle cell lymphoma  \[[76](#CIT0076)\]Idelalisib I, IIRelapsed indolent non-Hodgkin lymphoma (NHL)fatigue, gastrointestinal discomforts, dermatologic adverse effects, pyrexia, hematological toxicities (neutropenia, anemia, thrombocytopenia), elevated AST/ALT, pneumonia, colitis Combined with lenalidomide and rituximab: hepatoxicity and immune suppression\[[77](#CIT0077)\]\[[78](#CIT0078)--[81](#CIT0081)\]  I, IIIRelapsed or refractory CLLHypokalemia \[[82](#CIT0082)--[85](#CIT0085)\]  IIChronic lymphocytic leukemia or small lymphocytic leukemia treatment-naive older patients; AEs-related death: pneumonitis, sepsis\[[86](#CIT0086),[87](#CIT0087)\]  IIRelapsed or refractory CLL or NHL terminated early due to pneumonitis in 18% of patients; 2 AE-related death: pneumonitis\[[88](#CIT0088)\]  IIRelapsed or refractory Hodgkin lymphoma 60% deaths during the study or long term follow up (1 death occurred on study -- hypoxia)\[[89](#CIT0089)\]  --B-cell prolymphocytic leukemia Case study n = 5\[[90](#CIT0090)\]  IRelapsed mantle cell lymphoma and relapsed follicular lymphoma Idelalisib with lenalidomide and rituximab; terminated due to serious toxicity;\[[91](#CIT0091)\]  IAllergic rhinitisNasopharyngitis, myalgia  \[[92](#CIT0092)\]Nemiralisib IIPersistent, uncontrolled asthmaCough Administered through inhaler; negative results\[[93](#CIT0093)\]CopanlisibClass I pan- PI3KsIAdvanced solid tumors and non-Hodgkin's lymphomasHyperglycemia, gastrointestinal discomforts, hypertension, dermatologic adverse effects, fatigue, mucositis, elevated aspartate aminotransferase and alanine aminotransferase, thrombocytopenia, neutropenia, anemia, pneumonitisHypertension \[[94](#CIT0094)\] IAdvanced or refractory solid tumors \[[95](#CIT0095)\] IAdvanced cancerAs above with atrial fibrillation, sinus tachycardia \[[96](#CIT0096)\] IIIndolent or aggressive malignant lymphomaAs above with pancreatitis, infectionAs above with cardiac disorders (not being specified in the article) \[[97](#CIT0097)\]Buparlisib\
(BKM120) IAdvanced solid tumorsGastrointestinal discomforts, hyperglycemia, fatigue, dermatologic adverse effects, stomatitis, elevated transaminase, hypertension, psychiatric disorders, confusion, increased lipase, increased serum amylaseHypertension \[[98](#CIT0098)\] IbHER2-positive advance or metastatic breast cancer \[[99](#CIT0099)\] IMetastatic renal cell carcinoma7 in 28 patients discontinued therapy because of toxicity\[[100](#CIT0100)\] I, IIIHormone receptor-positive metastatic breast cancer \[[101](#CIT0101)--[103](#CIT0103)\] IRelapsed/refractory acute leukemias \[[104](#CIT0104)\] IIAdvanced or recurrent endometrial carcinomaStopped before end of recruitment for toxicity\[[105](#CIT0105)\] IIRecurrent glioblastoma \[[106](#CIT0106)\] IMetastatic breast cancerAs above with neutropenia, peripheral neuropathy \[[107](#CIT0107)\] II/IIIAdvanced or metastatic breast cancer \[[108](#CIT0108)\] IHigh-grade ovarian and breast cancerAs above with thrombocytopenia, leukopenia, anemia, lymphopenia \[[109](#CIT0109)\] IAdvanced solid tumors \[[110](#CIT0110)\] IbAdvanced solid tumorsAs above with increased creatine kinase \[[111](#CIT0111)\][^1]

Clinical trials of inhibitors that block PI3Kα commonly reported hyperglycemia as the major side effect \[[18](#CIT0018)--[30](#CIT0030)\], which is unsurprising considering the critical involvement of PI3Kα in insulin signaling \[[31](#CIT0031),[32](#CIT0032)\]. Corrected QT (QTc) prolongation was observed for alpelisib (BYL719) \[[18](#CIT0018),[23](#CIT0023)\], but not for serabelisib (MLN1117) \[[26](#CIT0026)\] or taselisib (GDC0032) \[[27](#CIT0027)\] ([Table 1](#T0001)). General inhibition of PI3K and/or tyrosine kinase activity had been linked to cardiotoxicity and drug-related heart failure \[[13](#CIT0013),[14](#CIT0014)\]. Pan-PI3K inhibitors exhibit similar cardiac side effects as PI3Kα inhibition suggesting that the effects might be due to inhibition of this PI3K. So far, arrhythmogenic side effects are known for the pan-PI3K inhibitor copanlisib \[[15](#CIT0015)\]. For copanlisib, which now has regulatory approval, prolonged QT~c~ (ΔQT~cB~ ≥ 60 ms) was found in 6.6% of patients, prompting a request by the FDA for further monitoring \[[15](#CIT0015)\].

Tyrosine kinase inhibitors may indirectly suppress PI3Kα. Inhibition of PI3Kα has been put forward as an explanation of the arrhythmogenic effects of ibrutinib \[[33](#CIT0033)\]. Only ibrutinib (Bruton tyrosine kinase inhibitor) has been linked to instances of atrial fibrillation, ventricular arrhythmias, and sudden cardiac death \[[34](#CIT0034)--[36](#CIT0036)\].

Cardiac effects of PI3Kα inhibition in diabetes {#S0003}
===============================================

In murine models of diabetes, reduced sensitivity to insulin is associated with diminished PI3Kα activity which has been linked to both hyperglycemia and arrhythmias \[[37](#CIT0037),[38](#CIT0038)\]. Prolongation of the action potential and QTc interval was observed in different animal models of diabetes \[[39](#CIT0039),[40](#CIT0040)\]. The reduced PI3Kα activity causes the dis-inhibition (activation) of late Na^+^ current leading to prolongation of the action potential \[[37](#CIT0037),[38](#CIT0038)\]. Conversely, upregulation of PI3Kα activity in the heart has been shown to protect from ventricular arrhythmias and sudden death associated with pathological hypertrophy and heart failure \[[17](#CIT0017),[41](#CIT0041)\].

PI3Kα in cardioprotection {#S0004}
=========================

PI3Kα signaling has recently emerged as an important cardioprotective pathway. In murine animal models, PI3Ka pathway has been shown to be protective in the model of tamoxifen toxicity \[[42](#CIT0042)\] and various models of heart failure \[[6](#CIT0006),[43](#CIT0043),[44](#CIT0044)\]. For pressure overload model of heart failure, a recent study by Patel et al. \[[6](#CIT0006)\]. elucidated a mechanism underlying the accelerated progression of heart failure observed in a murine model of PI3Kα deficiency, suggesting that PI3Kα activation is part of a compensatory response during heart failure. They also reported reduced PI3Kα activity in human and dog hearts with dilated cardiomyopathy, additionally suggesting that PI3Kα is a part of compensatory response mechanisms to maintain heart function under adverse conditions \[[6](#CIT0006)\]. In the murine model of ischemic preconditioning, PI3Kα was also found to be the key PI3K isoform to limit myocardial infarct size \[[43](#CIT0043)\]. In the murine model of doxorubicin-induced heart failure, the loss of PI3Kα exacerbates cardiac atrophy, leading to biventricular atrophy associated with right ventricular dysfunction \[[44](#CIT0044)\]. Similarly, patients receiving anthracyclines and trastuzumab, which indirectly inhibits PI3Kα activity, exhibit biventricular dysfunction and reduced heart mass \[[45](#CIT0045)\]. Taken together, the PI3Kα pathway appears to play a crucial cardioprotective role.

PI3Kα in compensatory response during heart failure {#S0005}
===================================================

Under quiescent conditions, lack or reduced PI3Kα activity does not significantly affect heart function \[[6](#CIT0006),[46](#CIT0046),[47](#CIT0047)\], but lack of PI3Kα activity is known to accelerate heart failure progression in the pressure overload model of heart failure \[[6](#CIT0006),[47](#CIT0047)\]. However, the exact mechanisms of this increased susceptibility to heart failure were unknown. Recently, Patel et al \[[6](#CIT0006)\]. proposed that in response to biomechanical stress, PI3Kα is recruited to intercalated disks and the plasma membrane where it produces PIP3, which is required to suppress the activity of gelsolin (GSN), an actin-severing protein. When PI3Kα activity is suppressed, GSN activity is markedly increased, leading to lower levels of actin polymerization and a less resilient actin cytoskeleton. Tissue of human and dog hearts with dilated cardiomyopathy also showed reduced levels of actin polymerization, and in human samples, there was a negative correlation between cardiac function and actin depolymerization (the lower ejection fraction corresponded to higher depolymerization levels) \[[6](#CIT0006)\]. In addition, human and canine hearts with dilated cardiomyopathy showed reduced PI3Kα activity. In a murine dilated cardiomyopathy model, the exacerbation of cardiac dysfunction in PI3Kα-deficient mice was prevented by experimental GSN deficiency, suggesting that PI3Kα is an important *in vivo* cytoskeletal regulator during cardiac remodeling in pressure overload heart failure. In the proposed framework \[[6](#CIT0006)\], PI3Kα produces PIP3 which suppresses GSN activity, preventing depolymerization of the actin cytoskeleton by GSN ([Figure 1a](#F0001)). In the case of heart failure, reduced PI3Kα activity leads to low PIP3 levels and increased GSN activity, which in turn favors the depolymerization of the actin cytoskeleton ([Figure 1b](#F0001)). Another possible mechanism of cardioprotection mediated by PI3Kα is suppression of late Na^+^ current by PI3Kα-generated PIP3 \[[7](#CIT0007),[48](#CIT0048)\]. Since activation of late Na^+^ current accompanied heart failure in the pressure overload model\[[49](#CIT0049)\], lack of PI3Kα activity and the ensuing reduction in PIP3 to suppress late Na^+^ current may contribute to the accelerated transition to heart failure. The link between PI3Kα inhibition, late Na^+^ current, Ca^2+^ cycling, and arrhythmias is discussed in more detail below.10.1080/19336950.2019.1697127-F0001Figure 1.Regulation of actin cytoskeletal integrity by PI3Kα in the normal heart and heart failure. (a) Normal heart: PI3Kα produces PIP3, which inhibits gelsolin (GSN) activity preventing actin severing action of GSN and favoring a polymerized state of the cytoskeleton (prevalence of F-actin). (b) Heart failure: diminished PI3Kα activity results in reduced PIP3 levels, which leads to active GSN severing F-actin and depolymerized cytoskeleton (prevalence of G-actin).

PI3Kα and QT prolongation {#S0006}
=========================

*PI3Kα upregulation and QT*. PI3Kα activity controls expression levels of many channel forming proteins (K^+^: Kir, Kv, TASK; Ca^2+^: Cav1; Na^+^: SCN5A). In murine models, an increase in PI3Kα activity, for example, due to exercise leads to an increase in the protein levels of K^+^, Ca^2+^, and Na^+^ channels as well as their current densities \[[17](#CIT0017)\]. Increasing PI3Kα activity via expression of constitutively-active PI3Kα also produces higher protein levels and current densities \[[41](#CIT0041)\]. Overall, upregulation of PI3Kα due to exercise or overexpression did not affect QT interval due to balanced increase in protein levles of both repolarizing K^+^ channels (Kir, Kv, TASK) and depolarizing channels (Ca^2+^: Cav1; Na^+^: SCN5A). Moreover, PI3Kα upregulation was protective against arrhythmias, pathological hypertrophy, and dilated cardiomyopathy \[[16](#CIT0016),[17](#CIT0017),[41](#CIT0041)\].

*PI3Kα inhibition prolongs QT*. Over the last decade, there has been a steady accumulation of observations linking pharmacological inhibition of PI3Kα to activation of late Na current (I~Na-L~). Apparently, some classical blockers of rapidly-activating delayed rectifier K^+^-channels, such as dofetilide and E4031, can also inhibit PI3Kα activity and activate I~Na-L~ \[[50](#CIT0050)\]. In patients, ibrutinib (inhibitor of Bruton tyrosine kinase, an upstream effector of PI3Kα) increased cardiac disorders (2-fold) and atrial fibrillation (3-fold) \[[34](#CIT0034)\], as well as instances of sudden death and ventricular arrhythmias \[[35](#CIT0035),[36](#CIT0036)\]. In mice, high doses of ibrutinib produce analogous results (an increase in susceptibility to induced atrial and ventricular arrhythmias) and was associated with inhibition of PI3Kα activity \[[51](#CIT0051)\].

In murine models, inhibition of PI3Kα produced QT prolongation or long-QT (LQT) and was associated with activation of I~Na-L~ \[[50](#CIT0050)\], whereas in canine cardiac myocytes the use of pan PI3K inhibitors lead to inhibition of delayed rectifier K^+^ currents and activation of I~Na-L~ \[[52](#CIT0052)\]. The isoform-specific PI3Kα inhibitor (BYL719) increased I~Na-L~ and resulted in a triggered activity in murine cardiomyocytes \[[48](#CIT0048)\] and isolated murine hearts \[[7](#CIT0007),[53](#CIT0053)\], but had no effect on murine K^+^ currents \[[7](#CIT0007)\]. These results suggest a straightforward link between PI3Kα activity, the prolongation of the action potential, and QT interval ([Figure 2](#F0002)). In this framework, an indirect inhibition of PI3Kα activity by cancer therapies by receptor tyrosine kinase-based therapies (e.g., ibrutinib) \[[34](#CIT0034)--[36](#CIT0036)\] or directly (e.g., alpelisib) \[[18](#CIT0018),[23](#CIT0023)\] may reduce PI3Kα activity leading to reduced PIP3. Since PIP3 suppresses I~Na-L~, a reduction in PIP3 levels will dis-inhibit (activate) I~Na-L~, which as a depolarizing current will promote action potential and result in QT prolongation ([Figure 2](#F0002)). This QT prolongation due to PI3Kα inhibition may be somewhat compensated in large mammals (including humans) by the influence of PIP3 on L-type Ca^2+^ current (I~Ca,L~). Indeed, PIP3 has *stimulatory* effects on depolarizing L-type Ca^2+^ current (I~Ca,L~); therefore, the reduction of PIP3 levels due to PI3Kα inhibition will promote QT prolongation *via* I~Na-L~ and counteract it *via* I~Ca,L~ ([Figure 2](#F0002)). A promising approach therefore to prevent QT prolongation is to block the activation of I~Na-L~ with adjuvant therapy (*e.g*., ranolazine) ([Figure 2](#F0002)) \[[7](#CIT0007)\]. Besides direct pro-arrhythmic effects of I~Na-L~ activation, the increased I~Na-L~ may potentially contribute to the development dilated cardiomyopathy since increased influx of Na^+^ due to gain-of-function mutations in *SCN5A* and *SCN10* (genes encoding Na^+^ channels) has been implicated in the development of heart failure in rodents \[[49](#CIT0049)\] and was associated with dilated cardiomyopathy \[[54](#CIT0054)\] as well as sudden cardiac death \[[55](#CIT0055),[56](#CIT0056)\]. Another implication of increased I~Na-L~ activity is sarcoplasmic reticulum Ca^2+^ overload, which we will discuss below.10.1080/19336950.2019.1697127-F0002Figure 2.Cancer therapies prolong QT interval via inhibition of PI3Kα. Inhibition of PI3Kα activity either at receptor tyrosine kinase (RTK) step or directly at Pi3Kα will lead to a reduction in PIP3 levels, which exert an inhibitory effect on late I~Na~. In the absence of PIP3-related inhibition, additional depolarizing I~Na~ will prolong action potential and QT interval. The QT prolongation could be moderated in large mammals due to the opposite effect of PIP3 on L-type Ca^2+^ current (I~Ca~). Reduction in PIP3 levels will translate in the smaller amplitude of depolarizing current I~Ca~, which will favor QT shortening.

PI3Kα, Ca^2+^ cycling, and triggered arrhythmias {#S0007}
================================================

Dis-inhibition of I~Na-L~ due to inhibition of PI3Kα \[[7](#CIT0007),[48](#CIT0048),[50](#CIT0050),[52](#CIT0052)\] can exacerbate Ca^2+^ overload by modulating Ca^2+^ cycling and α-adrenergic stimulation \[[7](#CIT0007)\], both of which are important contributors to the development of several arrhythmias \[[56](#CIT0056)--[58](#CIT0058)\]. In this framework, dis-inhibited I~Na-L~ will produce an additional Na^+^ influx (I~Na-L~; see (1) in [Figure 3a](#F0003)), which will increase cytosolic Ca^2+^ either *via* a reverse mode of Na^+^-Ca^2+^ exchanger at the plateau of action potential (2) or by reduction of Ca^2+^ extrusion *via* forward mode during resting potential. Increase in cytosolic Ca^2+^ will facilitate Ca^2+^ uptake to the sarcoplasmic reticulum (SR) *via* SERCa2 (3) leading to Ca^2+^ overload (4) ([Figure 3a,b](#F0003)) \[[7](#CIT0007)\]. This Ca^2+^ overload will promote prolongation of the action potential, abnormal automaticity, early and delayed afterdepolarization, and increased dispersion of repolarization \[[59](#CIT0059),[60](#CIT0060)\]. This increase in SR Ca^2+^ load is additive to α-adrenergic stimulation \[[7](#CIT0007)\] and thus will create a risky situation similar to catecholaminergic polymorphic ventricular tachycardia (CPVT) \[[58](#CIT0058),[61](#CIT0061)\]. The combined effect of I~Na-L~ and α-adrenergic stimulation will lead to an excessive Ca^2+^ load that may result in spontaneous Ca^2+^ release, which will generate depolarizing current (I~NCX~) *via* forward mode of NCX producing delayed afterdepolarization (DAD) and possibly triggered activity (premature action potential) ([Figure 3c](#F0003)) \[[7](#CIT0007)\]. In this framework, excessive Ca^2+^ overload can be prevented either by inhibition of I~Na-L~ by ranolazine or reverse mode of NCX by KB-R7943 ([Figure 3a](#F0003)) \[[7](#CIT0007)\].10.1080/19336950.2019.1697127-F0003Figure 3.Effect of PI3Kα on Ca^2+^ cycling, α-adrenergic stimulation, and arrhythmias. (a) Effect of the PI3Kα inhibition on Ca^2+^ cycling. Inhibition of PI3Kα (1) reduces the inhibitory action of PIP3 on late Na^+^ current (I~Na-L~). Increased I~Na-L~ will generate an influx of Na^+^, which will promote the influx of Ca^2+^ via Na^+^-Ca^2+^ exchanger (NCX) (2). Increased Ca^2+^ influx and thus increased cytosolic Ca^2+^ will stimulate additional Ca^2+^ uptake via sarco-endoplasmic reticulum Ca^2+^ ATPase type 2 (SERCa2) (3) leading to increased Ca^2+^ levels in sarcoplasmic reticulum or Ca^2+^ overload (4). (b) Schematic representation of the sequence of the events depicted in *A*. (c) Interaction of activation of late I~Na~ and α-adrenergic stimulation. Both late I~Na~ and α-adrenergic stimulation are known to contribute to sarcoplasmic (SR) Ca^2+^ overload. The SR Ca^2+^ overload may result in spontaneous Ca^2+^ release (increase in cytoplasmic Ca^2+^~i~) via ryanodine receptor channels (RYR2). An increase in cytoplasmic Ca^2+^ will produce depolarizing current via the forward mode of NCX (NCX(F)) leading to arrhythmogenic delayed afterdepolarization (DAD).

PI3Kα inhibition and heart failure in the clinic {#S0008}
================================================

Besides the arrhythmogenic effects of PI3Kα inhibition associated with I~Na-L~ activation and related Ca^2+^ overload, these processes may contribute to the development and exacerbate heart failure. The activation of I~Na-L~ and increased Ca^2+^ influx *via* NCX have been linked to the development of heart failure in a murine pressure overload model \[[49](#CIT0049)\] *via* hypertrophic calcineurin-NFAT signaling \[[62](#CIT0062)\]. In heart failure, when α-adrenergic signaling is upregulated to maintain cardiac output \[[63](#CIT0063)\], an additional Ca^2+^ from I~Na-L~-NCX axis would compound with the effects of α-adrenergic stimulation resulting in the accelerated progression of heart failure. Pro-arrhythmic effects of PI3Kα inhibition will be amplified because of the higher levels of Na^+^-Ca^2+^ exchanger protein observed both in human failing heart \[[64](#CIT0064)\] and in rodent models of heart failure \[[65](#CIT0065)\].

This means that the risk of cardiac-specific side effects of PI3Kα inhibition will be greater in the elderly patients who are more likely to suffer from heart failure or preexisting cardiac dysfunctions \[[66](#CIT0066)\]. Polymorphisms in genes involved in all steps that produce Ca^2+^ overload ([Figure 3a,b](#F0003)) could also contribute to susceptibility of PI3Kα-dependent cardiac side effects. Polymorphisms and mutations in *SCN5A* and *SCN10A* (genes that are responsible for Na^+^ influx *via* I~Na-L~) have already been linked to dilated cardiomyopathy, arrhythmias, and sudden cardiac death \[[54](#CIT0054)--[56](#CIT0056),[67](#CIT0067)\]. Other LQT-related polymorphisms and mutations may aggravate QT prolongation due to PI3Kα inhibition exacerbating arrhythmic risk. Additionally, since PI3Kα inhibition leads to Ca^2+^ overload, polymorphisms and mutations related to CPVT, especially the ones that increase sensitivity to Ca^2+^ overload \[[58](#CIT0058)\], will also magnify arrhythmogenic effects PI3Kα inhibition. The link between genetic background and arrhythmogenic effects of PI3Kα inhibition warrants further in-depth studies.

Currently, there are two possible approaches to mitigate cardiotoxicity related to PI3Kα inhibition. One is the use of an I~Na-L~ blocker (e.g., ranolazine) that will prevent AP prolongation and Ca^2+^ overload resulting from inhibition of PI3Kα \[[7](#CIT0007),[68](#CIT0068)\]. Ranolazine is known to improve heart function in heart failure patients (not related to drug-induced cardiotoxicity) \[[69](#CIT0069)--[71](#CIT0071)\] as well as to prevent anthracycline-induced cardiotoxicity \[[72](#CIT0072)\]. The other less explored approach is to block the reverse mode of NCX; however, currently, there are no approved drugs to achieve this effect.
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[^1]: AST/ALT, the ratio of aspartate transaminase (AST) to alanine transaminase (ALT); CCL, chronic lymphocytic leukemia; HR, hormone receptor; NHL, non-Hodgkin lymphoma
